• 1
    Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64(Suppl. 2): ii30ii36.
  • 2
    Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica 1978; 157: 238244.
  • 3
    Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64(Suppl. 2): ii65ii68.
  • 4
    van de Kerkhof PC, Kragballe K, Austad J et al. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 2006; 16: 167171.
  • 5
    Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev 2014; 13: 490495.
  • 6
    Gourraud PA, Le GC, Puzenat E, Aubin F, Ortonne JP, Paul CF. Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis. J Invest Dermatol 2012; 132: 21712175.
  • 7
    Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010; 130: 933943.
  • 8
    Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280284.
  • 9
    Sampogna F, Tabolli S, Abeni D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol 2012; 92: 299303.
  • 10
    Ersser SJ, Surridge H, Wiles A. What criteria do patients use when judging the effectiveness of psoriasis management? J Eval Clin Pract 2002; 8: 367376.
  • 11
    Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? facts and controversies. Clin Dermatol 2010; 28: 6772.
  • 12
    Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45: 7276.
  • 13
    Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 2000; 70: 567571.
  • 14
    Masmoudi J, Maalej I, Masmoudi A, Rached H, Rebai A, Turki H. Jaoua A [Alexithymia and psoriasis: a case-control study of 53 patients]. Encephale 2009; 35: 1017.
  • 15
    Richards HL, Fortune DG, Griffiths CE, Main CJ. Alexithymia in patients with psoriasis: clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. J Psychosom Res 2005; 58: 8996.
  • 16
    Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729736.
  • 17
    Maza A, Richard MA, Aubin F et al. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Br J Dermatol 2012; 167: 643648.
  • 18
    European Medicines Agency, Committee For Medicinal Products For Human Use (CHMP). Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. [WWW document]. URL (last accessed: 16 January 2014).
  • 19
    Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 14331440.
  • 20
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210216.
  • 21
    Finlay AY, Kelly SE. Psoriasis–an index of disability. Clin Exp Dermatol 1987; 12: 811.
  • 22
    McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997; 36: 388394.
  • 23
    McKenna SP, Cook SA, Whalley D et al. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 2003; 149: 323331.
  • 24
    Dauden E, Herrera E, Puig L et al. Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. Health Qual Life Outcomes 2012; 10: 56.
  • 25
    U.S.Department of Health and Human Services, Food and Drug Admin-istration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. [WWW document]. URL (last accessed: 16 January 2014).
  • 26
    Charmaz K. Grounded theory. In: Smith JA, Harre R, van Langenhove L, eds. Rethinking Methods in Psychology. Sage, London, UK, 1995: 2749.
  • 27
    Charmaz K. Grounded Theory in the 21st Century, 3rd edn. Sage, Thousand Oaks, CA, 2005.
  • 28
    Murh T. User's Manual for Atlas.ti 6.0. Atlas.ti, Berlin, 2004.
  • 29
    Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn. McGraw-Hill Inc, New York, 1994.
  • 30
    Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validity in health status measurements: a clarification. J Clin Epidemiol 1989; 42: 403408.
  • 31
    Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206: 307315.
  • 32
    Cohen J. Statistical Power Analysis for the Behavioral Sciences. Academic Press, New York, 1977.
  • 33
    Mapi Research Trust. REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire. [WWW document] 2014. URL (last accessed: 10 April 2014).
  • 34
    Puzenat E, Bronsard V, Prey S et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24(Suppl. 2): 1016.
  • 35
    Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573.
  • 36
    Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005; 15: 279283.
  • 37
    Prey S, Paul C, Bronsard V et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24(Suppl. 2): 3135.
  • 38
    Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004; 10: 318325.